FDA approves drug for nausea and vomiting from Chemo

The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy.
Nausea and vomiting are common side effects experienced by cancer patients undergoing chemotherapy. Symptoms can persist for days after the chemotherapy drugs are administered. Nausea and vomiting that occurs from 24 hours to up to 120 hours after the start of chemotherapy is referred to as delayed phase nausea and vomiting, and it can result in serious health complications. Prolonged nausea and vomiting can lead to weight loss, dehydration and malnutrition in cancer patients leading to hospitalization.
“Chemotherapy-induced nausea and vomiting remains a major issue that can disrupt patients' lives and sometimes their therapy,” said Amy Egan, M.D., M.P.H., deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.

The FDA approved rolapitant (Varubi, Tesaro) to prevent delayed chemotherapy-induced nausea and vomiting in adults. The new medication can be provided to patients in tablet form along with other drugs that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing cancer chemotherapy. - See more at: http://www.pharmacypracticenews.com/ViewArticle.aspx?d=Web%2BExclusives&d_id=239&i=September+2015&i_id=1221&a_id=33592#sthash.X5OBcvze.dpuf